Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01850004 · ClinicalTrials.gov registry record · Phase 2

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

A Phase 2 study of Chronic Phase Chronic Myeloid Leukemia, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
84
Enrollment target
20
Study locations

NCT01850004 is a Phase 2 study of Chronic Phase Chronic Myeloid Leukemia that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 84 participants. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01850004, a Phase 2 study of Chronic Phase Chronic Myeloid Leukemia, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
84 participants
Enrollment target
20
Study locations

Study Summary

The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained remission in the long-term, with undetectable or minimally detectable BCR-ABL residual disease.

Conditions Studied

Chronic Phase Chronic Myeloid Leukemia

Interventions

  • DRUG Dasatinib

Study Locations (20)

Other

  • Local Institution - 0012 - Paris
  • Local Institution - 0003 - Pessac
  • Local Institution - 0030 - Pierre-Bénite
  • Local Institution - 0002 - Vandœuvre-lès-Nancy
  • Local Institution - 0026 - Aachen
  • Local Institution - 0020 - Berlin
  • Local Institution - 0021 - Mannheim
  • Local Institution - 0022 - Ulm
  • Local Institution - 0025 - Catania
  • Local Institution - 0017 - Florence

California

  • Local Institution - 0006 - Duarte
  • Local Institution - 0029 - Los Angeles
  • Local Institution - 0001 - San Franisco

Texas

  • Local Institution - 0011 - Dallas
  • Local Institution - 0023 - Houston

Illinois

  • Local Institution - 0013 - Chicago

New Jersey

  • Local Institution - 0024 - Hackensack

New York

  • Local Institution - 0028 - New York

Ontario

  • Local Institution - 0005 - Toronto

Mecklenburg-Vorpommern

  • Local Institution - 0019 - Rostock

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2014-01-22
Est. Completion 2021-10-08
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01850004

The ClinicalTrials.gov registry entry for NCT01850004 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Phase Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.

NCT01850004 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Texas.

Frequently Asked Questions

What is clinical trial NCT01850004 about?

NCT01850004 is a clinical study titled "Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response". The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained remission in the long-term, with undetectable or minimally detectable BCR-ABL r...

What is the current status of trial NCT01850004?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2014-01-22. Estimated completion is 2021-10-08.

What conditions does trial NCT01850004 study?

This clinical trial studies the following conditions: Chronic Phase Chronic Myeloid Leukemia.

What interventions are being tested in trial NCT01850004?

The interventions under investigation include: Dasatinib (DRUG).

Who is sponsoring clinical trial NCT01850004?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01850004 being conducted?

This trial has 20 study locations across California, Illinois, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Phase Chronic Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Phase Chronic Myeloid Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.